一线托利帕利马布加化学疗法与化学疗法治疗晚期食道状细胞癌:一个成本效益分析
Jing-Wen Han1,2, Yu Zhong3, Jin Zhong4
1Department of Pharmacy, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
PloS one
|June 10, 2025
概括
第一线托利帕利马布加化疗为美国的晚期食道状细胞癌 (ESCC) 提供了具有成本效益的治疗方法. 这种组合提供了显著的价值,低于每年质量调整后生命年15万美元的支付意愿门.
科学领域:
- 在瘤学瘤学.
- 卫生经济学 卫生经济学
- 临床试验分析
背景情况:
- 晚期食道状细胞癌 (ESCC) 是一个重大的治疗挑战.
- 第一线治疗选择对于改善患者的治疗结果至关重要.
- 对医疗保健系统来说,评估新疗法组合的成本效益至关重要.
研究的目的:
- 评估托利帕利马布加化学疗法与单独化学疗法对高级ESCC的成本效益.
- 提供美国医疗保健支付者对这种治疗策略的看法.
- 确定组合疗法是否符合既定的成本效益值.
主要方法:
- 使用了基于JUPITER-06临床试验数据的10年分期生存模型.
- 从文献中纳入了直接的医疗成本和健康实用价值.
- 进行了敏感性分析 (单向和概率分析),以验证模型的稳定性.
主要成果:
- 托利帕利马布和化疗的结合导致增加了64483.3.3美元的成本.
- 观察到0.53个质量调整寿命年 (QALYs) 的增量有效性.
- 增量成本效益比 (ICER) 为每QALY122,771.67美元,低于15万美元的支付意愿门.
结论:
- 托里帕利马布与化疗相结合,代表了美国先进ESCC的成本效益高的第一线治疗方法.
- 从医疗保健支付者的角度来看,这些发现支持这种组合治疗的价值.
- 与单独的化疗相比,ICER建议有利的经济效益.
更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.2K
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.4K
相关概念视频
Cancer Survival Analysis
331
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
331
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
